-
公开(公告)号：US20200009050A1
公开(公告)日：2020-01-09
申请号：US16554765
申请日：2019-08-29
申请人： NANOBIOTIX
IPC分类号： A61K9/127 , A61K31/704 , A61K9/00 , A61K9/14 , A61K9/51
摘要： The present invention relates to a pharmaceutical composition comprising the combination of (i) a biocompatible nanoparticle and of (ii) a pharmaceutical compound of interest, to be administered to a subject in need of such a compound of interest, wherein the nanoparticle potentiates the compound of interest efficiency. The longest dimension of the biocompatible nanoparticle is typically between about 4 and about 500 nm, and its absolute surface charge value is of at least 10 mV (|10 mV|). The invention also relates to such a composition for use for administering the compound of interest to a subject in need thereof, wherein the nanoparticle and the compound of interest are to be administered to said subject between more than 5 minutes and about 72 hours from each other.
-
公开(公告)号：US20170258720A1
公开(公告)日：2017-09-14
申请号：US15529097
申请日：2015-11-24
申请人： NANOBIOTIX
IPC分类号： A61K9/127 , A61K9/00 , C07D491/14 , A61K31/37 , A61K9/51
CPC分类号： A61K9/1271 , A61K9/0019 , A61K9/0053 , A61K9/51 , A61K9/513 , A61K31/37 , A61K45/06 , A61K2121/00 , C07D491/14 , A61K2300/00
摘要： The present disclosure generally relates to the field of medicine. The present invention more specifically relates to a pharmaceutical composition comprising the combination of (i) at least one biocompatible nanoparticle comprising, or consisting in, at least one natural compound which is an inhibitor of a human CYP enzyme, the longest dimension of said nanoparticle being of at least 4 nm and less than 100 nm, and (ii) at least one compound of interest, typically at least one pharmaceutical compound, to be administered to a subject in need of such at least one compound of interest, wherein the combination of the at least one biocompatible nanoparticle and of the at least one compound of interest potentiates the at least one compound of interest's bioavailability. The at least one biocompatible nanoparticle is to be administered to the subject separately from the at least one compound of interest (preferably before), typically with an interval of between at least about 5 minutes (preferably more than about 5 minutes) and about 72 hours.
-
公开(公告)号：US20170258721A1
公开(公告)日：2017-09-14
申请号：US15529106
申请日：2015-11-24
申请人： NANOBIOTIX
IPC分类号： A61K9/127 , A61K9/00 , A61K31/704 , A61K9/51
摘要： The present invention relates to a pharmaceutical composition comprising the combination of (i) at least one biocompatible nanoparticle and (ii) at least one carrier comprising at least one pharmaceutical compound, to be administered to a subject in need of such a pharmaceutical compound, wherein the combination of the at least one biocompatible nanoparticle and of the at least one carrier comprising the pharmaceutical compound(s) potentiates the compound(s) of interest efficiency. The longest dimension of the biocompatible nanoparticle is typically between about 4 and about 500 nm and its absolute surface charge value is of at least 10 mV (|10 mV|). The carrier is in addition devoid of any surface sterically stabilizing agent. The invention also relates to such a composition for use for administering the pharmaceutical compound(s) in a subject in need thereof, wherein the at least one biocompatible nanoparticle and the at least one carrier comprising the at least one pharmaceutical compound are to be administered separately in a subject in need of said pharmaceutical compound, typically between more than 5 minutes and about 72 hours one from each other.
-
公开(公告)号：US20240000940A1
公开(公告)日：2024-01-04
申请号：US18039728
申请日：2021-11-30
申请人： NANOBIOTIX S.A.
CPC分类号： A61K41/0038 , A61P35/00 , A61N5/1001 , A61K33/42 , B82Y5/00 , A61N2005/1098
摘要： The invention concerns a particle and a composition comprising particles and their use in oncology. Specifically, the particles are porous, high-Z and carbon-free particles having internal pores, of longest dimension of at least 0.5 nm, and are for use in altering or destroying target cells in a mammal when said cells are exposed to ionizing radiation.
The present invention also provides a porous, high-Z and carbon-free particle wherein at least part of the porous structure of the particle is occupied by at least one therapeutic agent which is preferably for use in oncology.-
公开(公告)号：US20210015756A1
公开(公告)日：2021-01-21
申请号：US16955092
申请日：2018-12-18
申请人： NANOBIOTIX
发明人： MARIE-EDITH MEYRE , LAURENT LEVY , AGNÈS POTTIER
摘要： The present invention relates to the medical field, in particular to the treatment of neurological disorders. More specifically the present invention relates to a nanoparticle or nanoparticles' aggregate for use in prevention or treatment of a neurological disease or at least one symptom thereof in a subject without exposure of the nanoparticle or nanoparticles' aggregate to an electric field, and preferably without exposure thereof to any other external activation source, wherein the nanoparticle's or nanoparticles' aggregate's material is selected from a conductor material, a semiconductor material, an insulator material with a dielectric constant εijk equal to or above 200, and an insulator material with a dielectric constant εijk equal to or below 100. It further relates to compositions and kits comprising such nanoparticles and/or nanoparticles' aggregates as well as to uses thereof without exposure thereof to an electric field, and preferably without exposure thereof to any other external activation source.
-
公开(公告)号：US20170258718A1
公开(公告)日：2017-09-14
申请号：US15529102
申请日：2015-11-24
申请人： NANOBIOTIX
发明人： MARIE-EDITH MEYRE , AGNES POTTIER , LAURENT LEVY
IPC分类号： A61K9/127 , A61K31/704 , A61K9/51
CPC分类号： A61K9/127 , A61K9/14 , A61K9/51 , A61K31/704
摘要： The present invention relates to a pharmaceutical composition comprising the combination of (i) at least one biocompatible nanoparticle and (ii) at least one pharmaceutical compound, to be administered to a subject in need of such a pharmaceutical compound, wherein the nanoparticle potentiates the pharmaceutical compound efficiency. The longest dimension of the biocompatible nanoparticle is typically between about 4 and about 500 nm, its absolute surface charge value is of at least 10 mV (|10 mV|), and its Young modulus is less than 100 kPa. The invention also relates to such a composition for use for administering the pharmaceutical compound in a subject in need thereof, wherein the at least one nanoparticle and the at least one pharmaceutical compound are to be administered in the subject between more than 5 minutes and about 72 hours one from each other.
-
公开(公告)号：US20160184225A1
公开(公告)日：2016-06-30
申请号：US14892271
申请日：2014-05-30
申请人： NANOBIOTIX
IPC分类号： A61K9/127 , A61K31/704
CPC分类号： A61K9/127 , A61K9/0014 , A61K9/1271 , A61K9/14 , A61K9/5115 , A61K31/704 , Y10S977/773
摘要： The present invention relates to a pharmaceutical composition comprising the combination of (i) a biocompatible nanoparticle and of (ii) a pharmaceutical compound of interest, to be administered to a subject in need of such a compound of interest, wherein the nanoparticle potentiates the compound of interest efficiency. The longest dimension of the biocompatible nanoparticle is typically between about 4 and about 500 nm, and its absolute surface charge value is of at least 10 mV (|10 mV|). The invention also relates to such a composition for use for administering the compound of interest in a subject in need thereof, wherein the nanoparticle and the compound of interest are to be administered in said subject between more than 5 minutes and about 72 hours one from each other.
摘要翻译： 本发明涉及一种药物组合物，其包含以下组合：（i）生物相容性纳米颗粒和（ii）目标药物化合物的组合，待给予需要这种感兴趣的化合物的受试者，其中所述纳米颗粒增强化合物 的利益效率。 生物相容性纳米颗粒的最长尺寸通常在约4至约500nm之间，其绝对表面电荷值至少为10mV（| 10mV |）。 本发明还涉及用于在有需要的受试者中施用感兴趣的化合物的这种组合物，其中将所述受试者中的所述纳米颗粒和所述化合物在每个所述受试者中投与大于5分钟至约72小时之间 其他。
-
8.发明申请METHOD OF MONITORING THE RELEASE FROM LIPOSOMES OF A PRODUCT OF INTEREST USING SUPERPARAMAGNETIC NANOPARTICLES 审中-公开使用超级纳米颗粒监测利益相关产品的释放物的方法公开(公告)号：US20160038616A1
公开(公告)日：2016-02-11
申请号：US14886326
申请日：2015-10-19
发明人： AGNÈS POTTIER , LAURENT LEVY , MARIE-EDITH MEYRE , MATTHIEU GERMAIN , CYRIL LORENZATO , CHRIT MOONEN , PIERRE SMIRNOV
CPC分类号： A61K49/1812 , A61K9/0009 , A61K9/127 , A61K9/1271 , A61K9/1278 , A61K9/5094 , A61K9/5115 , A61K31/704 , A61K41/0028 , G01N24/088 , G01R33/5601
摘要： The present application relates to a method of monitoring the membrane permeabilization of liposome and the incidental release of a compound of interest.
摘要翻译： 本申请涉及监测脂质体的膜透化和感兴趣的化合物的偶然释放的方法。
-
公开(公告)号：US20220212008A1
公开(公告)日：2022-07-07
申请号：US17697976
申请日：2022-03-18
申请人： NANOBIOTIX S.A.
发明人： MARIE-EDITH MEYRE , AGNÈS POTTIER , LAURENT LEVY
摘要： The present invention relates to the medical field, in particular to the treatment of neurological disorders. More specifically the present invention relates to a nanoparticle or nanoparticles' aggregate for use in prevention or treatment of a neurological disease or at least one symptom thereof in a subject when the nanoparticle or nanoparticles' aggregate is exposed to an electric field, wherein the nanoparticle's or nanoparticles' aggregate's material is selected from a conductor material, a semiconductor material, an insulator material with a dielectric constant εijk equal to or above 200, and an insulator material with a dielectric constant εijk equal to or below 100. It further relates to compositions and kits comprising such nanoparticles and/or nanoparticles' aggregates as well as to uses thereof.
-
公开(公告)号：US20200086120A1
公开(公告)日：2020-03-19
申请号：US16472215
申请日：2017-12-19
申请人： NANOBIOTIX
发明人： LAURENT LEVY , MARIE-EDITH MEYRE , AGNÈS POTTIER
摘要： The present invention relates to the medical field, in particular to the enhancement of brain performances and to the treatment of pathological stress. More specifically the present invention relates to a nanoparticle or nanoparticles' aggregate for use in enhancing brain performances or in prevention or treatment of pathological stress in a subject when the nanoparticle and/or nanoparticles' aggregate is exposed to an electric field, wherein the nanoparticle's or nanoparticles' aggregate's material is selected from a conductor material, a semiconductor material, an insulator material with a dielectric constant εijk equal to or above 200, and an insulator material with a dielectric constant εijk equal to or below 100. It further relates to compositions and kits comprising such nanoparticles and/or nanoparticles' aggregates as well as to uses thereof.
-
-
-
-
-
-
-
-
-
搜索结果
13 条记录 (耗时 0.022 秒)
